The MAS-PEG platform uses various technologies to solve the in vivo defects such as short half-life and strong immunogenicity in macromolecular drugs, and long-acting, low-immunogenicity and long-term macromolecular drugs (therapeutic enzyme) will finally be achieved.
Our key technologies are as follows:
(1)Analysis and targeted gene transformation
The tertiary structure and epitope of macromolecular proteins were analyzed by computer-aided design. The spatial structure of macromolecular proteins were genetically modified and reevaluated subsequently according to the distribution of modifiable amino acids and epitopes on the evaluation space surface to screen out new expected substantial molecules.
(2) PEG saturation modification technology and quality evaluation
Our unique PEG modification technology isapplied toanalyze and evaluatethe PEG with different structure, size and modification type, as well as the critical quality attributesduring the modification process (modification site control, modification homogeneity control, high and low molecular control, etc.), therefore theparameters of modification process can be screened outwith strong reproducibility, good stability and controllable quality.
(3) Candidate structure screening in vivo animal evaluation system
Estimate the candidate
ingredients separately or jointly by in vivo animal model and evaluate the
difference through the index of immunogenicity, Anti - PEG, Anti - Enzyme, Anti
- PEG Enzyme, antibody type - IgM/IgG), distribution and metabolism, etc.,
screen out the most valuablecurative PEG protease of low
immunogenicity that be repeated use and be applied to clinical treatment.
PEG-BIO Biopharm Co,.(Chongqing) All right reserved 渝ICP备18012241号